For HER2-negative breast cancer, the advantages of platinum drugs in TNBC have been confirmed by many clinical studies.[12–17] Current guidelines[2,3] generally recommend platinum drugs for patients with TNBC carrying BRCA1/2 mutations, as the homologous recombination repair pathway after DNA damage is blocked due to BRCA1/2 mutations,[18,19] which can improve the sensitivity of platinum drugs to tumor cells. Here, ERBB2 is linked to neoplasm.